Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Industry Likely To See Increasing Geographic Diversification - Barr

This article was originally published in PharmAsia News

Executive Summary

The generic drug industry has myriad reasons to expand into non-U.S. markets and will continue to do so, according to Barr CEO Bruce Downey

You may also be interested in...

AB Or Not AB? Barr & Sandoz Ponder The Biogeneric Substitution Question

Generic manufacturers may not want substitutability for follow-on biologics, Barr CEO Bruce Downey said Sept. 19 at the Generic Pharmaceutical Association Annual Policy Conference in Washington, D.C

Generic Mobic, Celexa Launches Are Not Indicative Of Price Erosion – Teva

The deep discounts seen with some recent high profile generic launches are not reflective of an eroding generic pricing environment, Teva maintains

Barr’s Rationale For Pliva Merger: Business Synergy, Biogenerics Leadership

Barr is highlighting its complementary product portfolio and business model in its efforts to ward off competition from Actavis to acquire Pliva

Related Content





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts